112 related articles for article (PubMed ID: 2847745)
1. Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors.
DeFrees SA; Sawick DP; Cunningham B; Heinstein PF; Morré DJ; Cassady JM
Biochem Pharmacol; 1988 Oct; 37(20):3807-16. PubMed ID: 2847745
[TBL] [Abstract][Full Text] [Related]
2. Human spleen dihydroorotate dehydrogenase: a study of inhibition of the enzyme.
Gero AM; O'Sullivan WJ; Brown DJ
Biochem Med; 1985 Aug; 34(1):60-9. PubMed ID: 2996510
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).
Peters GJ; Sharma SL; Laurensse E; Pinedo HM
Invest New Drugs; 1987; 5(3):235-44. PubMed ID: 2822596
[TBL] [Abstract][Full Text] [Related]
4. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
5. Effect of 6-azauridine on de novo pyrimidine biosynthesis in cultured Ehrlich ascites cells. Orotate inhibition of dihydroorotase and dihydroorotate dehydrogenase.
Chen JJ; Jones ME
J Biol Chem; 1979 Jun; 254(11):4908-14. PubMed ID: 35542
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies on dihydroorotate dehydrogenase from P. berghei and the mouse reticulocyte.
Gero AM; Finney KG; Bennett JC; O'Sullivan WJ
Aust J Exp Biol Med Sci; 1981 Aug; 59(4):477-90. PubMed ID: 6271112
[TBL] [Abstract][Full Text] [Related]
7. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
8. Enzymes of de novo pyrimidine biosynthesis in Babesia rodhaini.
Holland JW; Gero AM; O'Sullivan WJ
J Protozool; 1983 Feb; 30(1):36-40. PubMed ID: 6134826
[TBL] [Abstract][Full Text] [Related]
9. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
10. Biochemical genetic analysis of pyrimidine biosynthesis in mammalian cells. II. Isolation and characterization of a mutant of Chinese hamster ovary cells with defective dihydroorotate dehydrogenase (E.C. 1.3.3.1) activity.
Stamato TD; Patterson D
J Cell Physiol; 1979 Mar; 98(3):459-68. PubMed ID: 220270
[TBL] [Abstract][Full Text] [Related]
11. Active site of dihydroorotate dehydrogenase A from Lactococcus lactis investigated by chemical modification and mutagenesis.
Björnberg O; Rowland P; Larsen S; Jensen KF
Biochemistry; 1997 Dec; 36(51):16197-205. PubMed ID: 9405053
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
13. Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.
Baldwin J; Farajallah AM; Malmquist NA; Rathod PK; Phillips MA
J Biol Chem; 2002 Nov; 277(44):41827-34. PubMed ID: 12189151
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
15. Specific inhibition of a family 1A dihydroorotate dehydrogenase by benzoate pyrimidine analogues.
Palfey BA; Björnberg O; Jensen KF
J Med Chem; 2001 Aug; 44(18):2861-4. PubMed ID: 11520193
[TBL] [Abstract][Full Text] [Related]
16. Insights into the mechanism of oxidation of dihydroorotate to orotate catalysed by human class 2 dihydroorotate dehydrogenase: a QM/MM free energy study.
Alves CN; Silva JR; Roitberg AE
Phys Chem Chem Phys; 2015 Jul; 17(27):17790-6. PubMed ID: 26087682
[TBL] [Abstract][Full Text] [Related]
17. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum.
Seymour KK; Lyons SD; Phillips L; Rieckmann KH; Christopherson RI
Biochemistry; 1994 May; 33(17):5268-74. PubMed ID: 7909690
[TBL] [Abstract][Full Text] [Related]
19. Roles in binding and chemistry for conserved active site residues in the class 2 dihydroorotate dehydrogenase from Escherichia coli.
Fagan RL; Palfey BA
Biochemistry; 2009 Aug; 48(30):7169-78. PubMed ID: 19530672
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Knecht W; Henseling J; Löffler M
Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
